Abstract: Disclosed herein are compositions and methods for treating inflammatory vascular diseases. Examples of inflammatory vascular disease include, but are not limited to, in-stent stenosis, coronary arterial diseases (CAD), angina, acute myocardial infarction, acute coronary syndrome, chronic heart failure (CHF), peripheral arterial occlusive diseases (PAOD), critical limb ischemia (CLI), cardiac, kidney, liver and intestinal ischemia, renal failure, cardiac hypertrophy, atherosclerosis, abdominal aortic aneurysm, vasculitis, carotid artery stenosis.

Abstract: The present invention provides novel nucleic acid and protein sequences for an estrogen-regulated GTP-binding protein gamma-12 subunit protein, as well as methods for using the sequences for modulating the effects of estrogen in mammalian cells, methods of detecting estrogen signaling in cells, and methods of identifying compounds capable of acting as an estrogen receptor agonist or antagonist.

Abstract: The present invention provides nucleic acid and protein sequences for a novel estrogen-regulated unconventional myosin protein, as well as methods for using the sequences for modulating the effects of estrogen in mammalian cells, methods of detecting estrogen signaling in cells, and methods of identifying compounds capable of acting as an estrogen receptor agonist or antagonist.

Abstract: A method of lowering plasma levels of Lp(a) or inhibiting the generation of apo(a) in a human by administering an effective amount of a compound of formula (I): ##STR1## wherein: R.sup.1 is hydrogen or alkyl;A, B, D, E, G, R.sup.2 and R.sup.3 each are hydrogen, and R.sup.4 is hydrogen in the .beta.-position; orR.sup.2 with R.sup.4, R.sup.4 with A, A with R.sup.3, B with D, D with E, or G with R.sup.2 is a bond, and the other substituents are each hydrogen; orR.sup.2 is alkyl in the .beta.-position and A, B, D, E, G, R.sup.3 and R.sup.4 are each hydrogen; orR.sup.3 is alkoxy in the .beta.-position and A, B, D, E, G, R.sup.2 and R.sup.4 are each hydrogen; orR.sup.4 is hydrogen in the .alpha.-position and A, B, D, E, G, R.sup.2 and R.sup.3 are each hydrogen; andR.sup.5 is methyl or ethyl, is disclosed.

Abstract: A method of lowering plasma levels of Lp(a) or inhibiting the generation of apo(a) in a human by administering an effective amount of a compound of the formula: ##STR1## wherein n is 0, 1 or 2:R.sup.1 is hydrogen, alkyl, alkanoyl, cycloalkanoyl, (alkoxy)alkanoyl, aroyl, aryloxycarbonyl;R.sup.2 is hydrogen, hydroxy, halo, alkoxy, alkanoyloxy, cycloalkanoyloxy, (alkoxy)alkanoyloxy, aroyloxy, aryloxycarbonyloxy;R.sup.3 is pyrrolidinyl or piperidinyl;or a pharmaceutically acceptable salt thereof;and a pharmaceutically acceptable excipient, is disclosed.